Aura Biosciences (NASDAQ:AURA) Insider Los Pinos Elisabet De Sells 16,928 Shares of Stock

Aura Biosciences, Inc. (NASDAQ:AURA) insider Los Pinos Elisabet De sold 16,928 shares of the firm’s stock in a transaction dated Tuesday, January 20th. The stock was sold at an average price of $4.86, for a total transaction of $82,270.08. Following the completion of the sale, the insider directly owned 457,463 shares of the company’s stock, valued at approximately $2,223,270.18. The trade was a 3.57% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link.

Los Pinos Elisabet De also recently made the following trade(s):

• On Wednesday, October 29th, Los Pinos Elisabet De sold 9,049 shares of Aura Biosciences stock. The stock was sold at an average price of $6.35, for a total value of $57,461.15.

Aura Biosciences Stock Performance

Shares of AURA stock opened at $4.97 on Wednesday. The stock has a 50 day moving average price of $5.74 and a 200 day moving average price of $6.13. Aura Biosciences, Inc. has a 52-week low of $4.34 and a 52-week high of $8.27. The firm has a market capitalization of $315.60 million, a P/E ratio of -2.56 and a beta of 0.46.

Aura Biosciences (NASDAQ:AURA) last announced its quarterly earnings data on Thursday, November 13th. The company reported ($0.40) EPS for the quarter, beating the consensus estimate of ($0.46) by $0.06. As a group, sell-side analysts forecast that Aura Biosciences, Inc. will post -1.66 EPS for the current year.

Hedge Funds Weigh In On Aura Biosciences

Large investors have recently bought and sold shares of the business. Tower Research Capital LLC TRC raised its position in shares of Aura Biosciences by 49.3% in the 2nd quarter. Tower Research Capital LLC TRC now owns 6,372 shares of the company’s stock worth $40,000 after acquiring an additional 2,104 shares in the last quarter. Water Island Capital LLC bought a new position in Aura Biosciences in the third quarter worth about $64,000. 49 Wealth Management LLC purchased a new stake in shares of Aura Biosciences during the third quarter valued at about $66,000. Invesco Ltd. bought a new stake in shares of Aura Biosciences in the 2nd quarter valued at about $76,000. Finally, China Universal Asset Management Co. Ltd. boosted its holdings in shares of Aura Biosciences by 24.3% in the 2nd quarter. China Universal Asset Management Co. Ltd. now owns 12,453 shares of the company’s stock valued at $78,000 after buying an additional 2,434 shares in the last quarter. Institutional investors own 96.75% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of equities research analysts recently weighed in on AURA shares. Evercore ISI started coverage on shares of Aura Biosciences in a report on Tuesday, November 25th. They set an “outperform” rating for the company. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Aura Biosciences in a research note on Monday, December 29th. One investment analyst has rated the stock with a Strong Buy rating, four have issued a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus price target of $20.50.

Aura Biosciences Company Profile

Aura Biosciences is a clinical‐stage biopharmaceutical company focused on the development of novel virus‐like particle (VLP) therapies for the treatment of cancer. By combining proprietary VLP technology with photoactivatable dyes, Aura aims to deliver highly selective photodynamic therapies that target and destroy tumor cells while sparing healthy tissue. The company’s platform is designed to address solid tumors in both ophthalmic and non‐ophthalmic settings, leveraging precision activation via near‐infrared light to induce localized tumor cell apoptosis and stimulate anti‐tumor immune responses.

The lead product candidate, AU-011, is being evaluated in patients with choroidal melanoma, a rare but potentially sight-threatening eye cancer.